These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28434174)

  • 21. Expression of LATS family proteins in ovarian tumors and its significance.
    Xu B; Sun D; Wang Z; Weng H; Wu D; Zhang X; Zhou Y; Hu W
    Hum Pathol; 2015 Jun; 46(6):858-67. PubMed ID: 25841306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
    Zhang Y; Miao Y; Yi J; Wang R; Chen L
    Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promoter hypermethylation of the CFTR gene and clinical/pathological features associated with non-small cell lung cancer.
    Son JW; Kim YJ; Cho HM; Lee SY; Lee SM; Kang JK; Lee JU; Lee YM; Kwon SJ; Choi E; Na MJ; Park JY; Kim DS
    Respirology; 2011 Nov; 16(8):1203-9. PubMed ID: 21585618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.
    Sato T; Soejima K; Arai E; Hamamoto J; Yasuda H; Arai D; Ishioka K; Ohgino K; Naoki K; Kohno T; Tsuta K; Watanabe S; Kanai Y; Betsuyaku T
    Oncol Rep; 2015 Sep; 34(3):1137-45. PubMed ID: 26134684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of large tumour suppressor (LATS) kinases modulates chemotherapy response in advanced non-small cell lung cancer.
    Luo SY; Kwok HH; Yang PC; Ip MS; Minna JD; Lam DC
    Transl Lung Cancer Res; 2020 Apr; 9(2):294-305. PubMed ID: 32420069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low LATS2 expression is associated with poor prognosis in non-small cell lung carcinoma.
    Jang SH; Oh MH; Cho H; Lee JH; Lee H; Ahn H; Kim H
    Pol J Pathol; 2019; 70(3):189-197. PubMed ID: 31820862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival.
    Bai Y; Wang YL; Yao WJ; Guo L; Xi HF; Li SY; Zhao BS
    Int J Clin Exp Pathol; 2015; 8(1):824-9. PubMed ID: 25755781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.
    Liu S; Chen X; Chen R; Wang J; Zhu G; Jiang J; Wang H; Duan S; Huang J
    Oncotarget; 2017 May; 8(22):36354-36367. PubMed ID: 28422739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HBP1 promoter methylation augments the oncogenic β-catenin to correlate with prognosis in NSCLC.
    Tseng RC; Huang WR; Lin SF; Wu PC; Hsu HS; Wang YC
    J Cell Mol Med; 2014 Sep; 18(9):1752-61. PubMed ID: 24895061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma.
    Liu X; Qi D; Qi J; Mao Z; Li X; Zhang J; Li J; Gao W
    Oncol Rep; 2016 Jan; 35(1):155-62. PubMed ID: 26530274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypermethylated LATS2 gene with decreased expression in female breast cancer: A case control study from North India.
    Sadaf ; Habib M; Khan MA; Najm MZ; Mallick MN; Sunita K; Shukla NK; Deo SVS; Husain SA
    Gene; 2018 Nov; 676():156-163. PubMed ID: 30010037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.
    Liu J; Ping W; Zu Y; Sun W
    Int J Clin Exp Pathol; 2014; 7(9):6040-7. PubMed ID: 25337249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
    Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
    Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
    Soria JC; Lee HY; Lee JI; Wang L; Issa JP; Kemp BL; Liu DD; Kurie JM; Mao L; Khuri FR
    Clin Cancer Res; 2002 May; 8(5):1178-84. PubMed ID: 12006535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
    Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
    Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
    Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
    Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance.
    Chen LJ; Li XY; Zhao YQ; Liu WJ; Wu HJ; Liu J; Mu XQ; Wu HB
    Pathol Res Pract; 2017 Aug; 213(8):882-888. PubMed ID: 28688608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
    Yang J; Liu H; Wang H; Sun Y
    Pathol Res Pract; 2013 Aug; 209(8):490-4. PubMed ID: 23827213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
    Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
    Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Down-regulation of SIX3 is associated with clinical outcome in lung adenocarcinoma.
    Mo ML; Okamoto J; Chen Z; Hirata T; Mikami I; Bosco-Clément G; Li H; Zhou HM; Jablons DM; He B
    PLoS One; 2013; 8(8):e71816. PubMed ID: 23977152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.